...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Molecular markers and determinants of prostate cancer metastasis.
【24h】

Molecular markers and determinants of prostate cancer metastasis.

机译：前列腺癌的分子标记和决定因素癌症转移。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although intensely studied, the molecular and biochemical determinants of prostate cancer development and progression remain ill-defined. Moreover, current markers and methodologies cannot distinguish between a tumor that will remain indolent and not impinge on patient survival, versus a tumor with aggressive traits culminating in metastatic spread and death. Once prostate cancer is confirmed the most significant threat to a patient's survival and quality of life involves tumor metastasis. Radical surgery notwithstanding, prostate cancer accounts for 10% of all cancer-related deaths primarily arising through development of metastasis. Metastasis markers demonstrating an acceptable level of reliability are an obvious necessity if disproportionate and costly treatment is to be avoided and a reasonably accurate determination of clinical prognosis and measure of successful response to treatment is to be made. Therapeutic strategies that specifically inhibit metastatic spread are not presently possible and may not become available in the immediate future. This is because, while localized tumorigenesis has been relatively amenable to detection, analysis and treatment, metastasis remains a relatively undefined, complex and underexplored area of prostate cancer research. New findings in the field such subclasses of genes called metastasis suppressors and cancer progression suppressors, have opened up exciting avenues of investigation. We review current methodological approaches, model experimental systems and genes presently known or having potential involvement in human prostate cancer metastasis. Copyright 2001 Wiley-Liss, Inc.
机译：虽然强烈的研究,分子和前列腺癌的生化因素开发和发展仍然是不明确的。此外,目前的指标和方法不能区分一个肿瘤保持懒惰和不影响病人生存,而肿瘤与积极的特质最终转移扩散和死亡。前列腺癌是最重要的确认威胁病人的生存质量生活包括肿瘤转移。尽管如此,前列腺癌占10%所有癌症相关死亡的主要产生通过发展的转移。标记显示一个可接受的水平可靠性是一个明显的必要性不成比例的和昂贵的治疗避免和一个合理准确的测定临床预后和衡量成功的对治疗的反应是。特别是抑制转移性的策略目前是不可能的,不得传播在不久的将来变得可用。因为,尽管局部肿瘤发生相对适合的检测、分析和治疗,转移仍然是一个相对未定义的,复杂的和未开发区域前列腺癌的研究。这样的子类的基因称为转移抑制肿瘤的抑制,开辟了令人兴奋的途径的调查。我们审查当前方法论的方法,目前模型实验系统和基因已知或有潜力参与人类前列腺癌转移。Wiley-Liss公司。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号